54895-28-2 Usage
Uses
Used in Pharmaceutical Industry:
(2R)-(4-amino-phenyl)-tert-butoxycarbonylamino-acetic acid is used as a building block for peptide synthesis, allowing for the creation of various pharmaceuticals and bioactive compounds. Its Boc protection group ensures selective deprotection during synthesis, facilitating the development of complex peptide structures.
Used in Peptide Synthesis:
(2R)-(4-amino-phenyl)-tert-butoxycarbonylamino-acetic acid is used as a key component in peptide synthesis, providing a protected amino acid that can be incorporated into peptide chains. The Boc group allows for selective deprotection, enabling the synthesis of a wide range of peptides with specific properties and functions.
Check Digit Verification of cas no
The CAS Registry Mumber 54895-28-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,8,9 and 5 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 54895-28:
(7*5)+(6*4)+(5*8)+(4*9)+(3*5)+(2*2)+(1*8)=162
162 % 10 = 2
So 54895-28-2 is a valid CAS Registry Number.
54895-28-2Relevant academic research and scientific papers
METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS
-
Page/Page column 14, (2008/12/08)
Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.
Substituted hydantoins
-
Page/Page column 14, (2008/06/13)
The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.
